NGM BIOPHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | -1.28% |
|
0.00% | +79.28% |
Presenter SpeechBrian Schoelkopf (Executives)Good morning and thank you for joining us today f...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +79.28% | 129M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.78% | 21.66B | |
| -18.35% | 20.77B | |
| -7.45% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- NGM Stock
- News NGM Biopharmaceuticals, Inc.
- Transcript : NGM Biopharmaceuticals, Inc. - Special Call
